Lysoway Therapeutics Secures Funding from MJFF to Develop Parkinson's Disease Treatment

CAMBRIDGE, Mass. — Lysoway Therapeutics, Inc., a biopharmaceutical firm focused on small molecule modulators of lysosomal ion channels, announced today that it has obtained a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This support is part of MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which targets promising candidates capable of slowing, stopping, or alleviating symptoms of Parkinson’s disease. The grant, totaling $2.93 million, will fund the preclinical and translational development of Lysoway’s innovative, brain-penetrant small molecule TRPML1 agonist. This funding will enable accelerated development of the company’s lead TRPML1 agonist, aiming to commence first-in-human trials by early 2026. The study will explore whether activating TRPML1 with this novel molecule can enhance lysosomal calcium channels, restore lysosomal function, and promote clearance of alpha-synuclein, a protein associated with Parkinson’s pathology. Valerie Cullen, PhD, Principal Investigator and SVP of Research at Lysoway, expressed gratitude for the grant: “Receiving this generous support from MJFF is an honor. TRPML1 plays a crucial role in cellula...